Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios
Asset Utilization RatioAssets AverageDebt RatioDebt to EquityEBIT MarginEBITDA MarginEBT MarginEnterprise ValueEquity AverageEquity RatioFCF MarginGross MarginInterest Coverage RatioInventory AverageInvested CapitalNet MarginOperating MarginReturn on AssetsReturn on Capital EmployedReturn on EquityReturn on Invested CapitalReturn on SalesTimes Interest Earned

60 Degrees Pharmaceuticals (SXTP) Return on Sales (2022 - 2025)

Historic Return on Sales for 60 Degrees Pharmaceuticals (SXTP) over the last 4 years, with Q3 2025 value amounting to 5.29%.

  • 60 Degrees Pharmaceuticals' Return on Sales rose 106700.0% to 5.29% in Q3 2025 from the same period last year, while for Sep 2025 it was 8.45%, marking a year-over-year increase of 77200.0%. This contributed to the annual value of 13.09% for FY2024, which is 19500.0% up from last year.
  • Per 60 Degrees Pharmaceuticals' latest filing, its Return on Sales stood at 5.29% for Q3 2025, which was up 106700.0% from 17.19% recorded in Q2 2025.
  • 60 Degrees Pharmaceuticals' Return on Sales' 5-year high stood at 81.53% during Q3 2023, with a 5-year trough of 151.27% in Q1 2023.
  • For the 4-year period, 60 Degrees Pharmaceuticals' Return on Sales averaged around 17.23%, with its median value being 13.72% (2025).
  • Over the last 5 years, 60 Degrees Pharmaceuticals' Return on Sales had its largest YoY gain of 1553200bps in 2024, and its largest YoY loss of -975000bps in 2024.
  • Quarter analysis of 4 years shows 60 Degrees Pharmaceuticals' Return on Sales stood at 44.91% in 2022, then plummeted by -136bps to 16.28% in 2023, then skyrocketed by 48bps to 8.48% in 2024, then soared by 38bps to 5.29% in 2025.
  • Its last three reported values are 5.29% in Q3 2025, 17.19% for Q2 2025, and 11.48% during Q1 2025.